JP2021508318A5 - - Google Patents

Download PDF

Info

Publication number
JP2021508318A5
JP2021508318A5 JP2020531663A JP2020531663A JP2021508318A5 JP 2021508318 A5 JP2021508318 A5 JP 2021508318A5 JP 2020531663 A JP2020531663 A JP 2020531663A JP 2020531663 A JP2020531663 A JP 2020531663A JP 2021508318 A5 JP2021508318 A5 JP 2021508318A5
Authority
JP
Japan
Prior art keywords
alkyl
halogen
heteroaryl
heterocycloalkyl
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020531663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021508318A (ja
JP7319977B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/064114 external-priority patent/WO2019113242A1/en
Publication of JP2021508318A publication Critical patent/JP2021508318A/ja
Publication of JP2021508318A5 publication Critical patent/JP2021508318A5/ja
Application granted granted Critical
Publication of JP7319977B2 publication Critical patent/JP7319977B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020531663A 2017-12-06 2018-12-05 チューブリン阻害剤 Active JP7319977B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595530P 2017-12-06 2017-12-06
US62/595,530 2017-12-06
PCT/US2018/064114 WO2019113242A1 (en) 2017-12-06 2018-12-05 Tubulin inhibitors

Publications (3)

Publication Number Publication Date
JP2021508318A JP2021508318A (ja) 2021-03-04
JP2021508318A5 true JP2021508318A5 (enExample) 2022-01-11
JP7319977B2 JP7319977B2 (ja) 2023-08-02

Family

ID=66658388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020531663A Active JP7319977B2 (ja) 2017-12-06 2018-12-05 チューブリン阻害剤

Country Status (8)

Country Link
US (3) US11040945B2 (enExample)
EP (1) EP3720436A4 (enExample)
JP (1) JP7319977B2 (enExample)
KR (1) KR20200104873A (enExample)
CN (1) CN111727042A (enExample)
AU (1) AU2018380132B2 (enExample)
TW (1) TWI828644B (enExample)
WO (1) WO2019113242A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019200683B2 (en) * 2018-02-01 2024-05-30 The University Of Sydney Anti-cancer compounds
JP7184383B2 (ja) * 2018-02-01 2022-12-06 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
WO2020118194A1 (en) 2018-12-07 2020-06-11 University Of Maryland, Baltimore NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS
KR20220041180A (ko) * 2019-07-31 2022-03-31 어클라리스 쎄라퓨틱스, 인코포레이티드 중소수화 mk2 경로 억제제 및 이를 이용하는 방법
US20210147441A1 (en) * 2019-09-26 2021-05-20 Agency For Science, Technology And Research (A*Star) Therapeutic compounds and methods of use thereof
WO2021127643A1 (en) 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
WO2021195507A1 (en) 2020-03-27 2021-09-30 Aclaris Therapeutics, Inc. Methods and compositions for treating viral infections
WO2022103149A1 (ko) * 2020-11-10 2022-05-19 주식회사 큐라클 신규한 카바졸 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
CN117120422A (zh) * 2021-03-23 2023-11-24 Gen1E生命科学公司 取代的萘基P38α丝裂原活化的蛋白激酶抑制剂
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2205732A1 (de) 1972-02-08 1973-08-16 Thomae Gmbh Dr K Neue 4-(4-biphenylyl)-butensaeurederivate
IT1044222B (it) 1972-05-23 1980-03-20 Zambeletti Spa L Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata
AT336594B (de) 1973-08-14 1977-05-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer 3-(4- biphenylyl)-buttersaureamiden
US5196543A (en) 1989-10-17 1993-03-23 Delalande S.A. 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy
EP0533753A1 (en) 1990-06-14 1993-03-31 Washington University Rna hydrolysis/cleavage
JP2969618B2 (ja) * 1995-06-27 1999-11-02 田辺製薬株式会社 ピリダジノン誘導体及びその製法
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP3060454B2 (ja) * 1996-12-26 2000-07-10 田辺製薬株式会社 医薬組成物
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
PL353455A1 (en) 1999-08-12 2003-11-17 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
BRPI0417354A (pt) 2003-12-03 2007-03-13 Cytopia Res Pty Ltd compostos inibidores de tubulina, composições e seus usos
RU2417993C9 (ru) 2004-05-18 2011-10-10 Шеринг Корпорейшн Замещенные 2-хинолилоксазолы, пригодные в качестве ингибиторов фдэ4
US20080124402A1 (en) 2004-10-29 2008-05-29 Merck & Co., Inc. N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators
CA2599538C (en) * 2005-03-15 2013-07-30 Nycomed Gmbh N-sulphonylpyrroles and their use as histone deacetylase inhibitors
WO2007123953A2 (en) 2006-04-19 2007-11-01 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US8778977B2 (en) 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
JP2009185010A (ja) 2008-02-08 2009-08-20 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害剤を含有する医薬
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
KR20120059558A (ko) * 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
US8518948B2 (en) * 2010-03-10 2013-08-27 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
ES2572387T3 (es) 2010-03-18 2016-05-31 Pasteur Institut Korea Compuestos anti-infecciosos
WO2013007708A1 (en) 2011-07-08 2013-01-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
US20130267712A1 (en) 2012-04-02 2013-10-10 Board Of Trustees Of Northern Illinois University Aromatic ketone synthesis with amide reagents and related reactions
CN105473559B (zh) 2013-03-15 2019-05-10 南洋理工大学 用于化学转化的羰基β-碳的活化
AR098475A1 (es) 2013-11-26 2016-06-01 Bayer Cropscience Ag Compuestos pesticidas y usos
WO2016067009A1 (en) 2014-10-28 2016-05-06 Redx Pharma Plc Compounds with activity against bacteria and mycobacteria
JP2018505170A (ja) * 2015-01-30 2018-02-22 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
FI3302448T3 (fi) 2015-06-04 2024-01-24 Aurigene Oncology Ltd Substituoituja heterosyklyylijohdannaisia cdk-inhibiittoreina

Similar Documents

Publication Publication Date Title
JP2021508318A5 (enExample)
JP2019518766A5 (enExample)
JP2019524883A5 (enExample)
JP2019031560A5 (enExample)
JP2017537940A5 (enExample)
JP2020510091A5 (enExample)
JP2016513130A5 (enExample)
JP2017512833A5 (enExample)
JP2017523169A5 (enExample)
JP2018529650A5 (enExample)
JP2015537020A5 (enExample)
JP2017511357A5 (enExample)
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
JP2015508092A5 (enExample)
JP2014521688A5 (enExample)
JP2018504437A5 (enExample)
JP2016121196A5 (enExample)
JP2017528502A5 (enExample)
JP2012092103A5 (enExample)
JP2015521195A5 (enExample)
JP2017509689A5 (enExample)
JP2016503797A5 (enExample)
JP2012513416A5 (enExample)
RU2017136715A (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
JP2016506386A5 (enExample)